Anandron (RU 23908) associated with orchiectomy in stage D prostate cancer. Preliminary results of a randomized, double-blind study.
A randomized, double-blind, multicenter trial was performed comparing the association of orchiectomy plus the nonsteroid antiandrogen Anandron (300 mg daily) to orchiectomy plus placebo in the treatment of patients with stage C or D prostate cancer. The results for 98 evaluable stage D patients with a median follow-up of 23.4 +/- 8.9 months are given. Although there was no statistically significant difference between the two treatments with regard to any parameter (subjective response, best objective response according to NPCP criteria, and progression-free interval and survival), the results were invariably in favor of the combined treatment, as already reported in other trials on Anandron.
Namer
M
M
Centre Antoine-Lacassagne, Nice, France.
Amiel
J
J
Toubol
J
J
D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D048289:Imidazolidines; D008297:Male; D015337:Multicenter Studies as Topic; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000601:surgery; D009919:Orchiectomy; D010919:Placebos; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000601:surgery*; D011897:Random Allocation; D012074:Remission Induction
D000726:Androgen Antagonists; D007093:Imidazoles; D048289:Imidazolidines; D010919:Placebos; C021277:nilutamide